Clinical investigations indicate that IGF-1 may protect against development of glucose intolerance or type-2 diabetes (48) and subcutaneous IGF-1 treatment reduces insulin required to maintain normoglycemia in type-1 diabetes patients (49–51). The gene discussed is IGF1; the disease is type 2 diabetes mellitus.